Response to "Results, rhetoric, and randomized trials: the case of donepezil".
Lisi
Donna
D
D000329:Advertising; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D016265:Conflict of Interest; D000077265:Donepezil; D004345:Drug Industry / Q000191:economics; D004363:Drug Utilization / Q000706:statistics & numerical data; D004465:Economic Competition; D019317:Evidence-Based Medicine / Q000706:statistics & numerical data*; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D008374:Manuscripts, Medical as Topic; D040541:Marketing; D018697:Nootropic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011578:Psycholinguistics; D016032:Randomized Controlled Trials as Topic
D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil